• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi, June 28

The UK Court of Appeal on Wednesday rejected an appeal by Ranbaxy Laboratories Ltd against a ruling issued last October that its atorvastatin product would infringe the main patent covering Pfizer Inc's blockbuster drug Lipitor.

The appeal court ruling upheld that of a lower court from October 2005 which ruled that Pfizer's European patent, number 409281, was invalid, but also found that Ranbaxy's proposed product would infringe Pfizer's patent 247633, which covers the active ingredient in the US firm's cholesterol-lowering drug. Ranbaxy in a statement said that it was evaluating this decision and will decide on its course of action shortly.

More Stories on : IPR | Pharmaceuticals | Ranbaxy Laboratories Ltd | Courts/Legal Issues

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
ADR/GDR rules relaxed for unlisted cos

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line